The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 1 week back · Material filings: 447 · All filings: 661

Material

Monday 9 Nov264 filings read · 204 material

  • 8-KFiled 9 Nov 2026All industries

    Uniti Group Inc.UNIT

    8-K · Item 2.02 — Results of operations

    Uniti reported Q3 2026 results with record fiber premises constructed (162,000) and highest Kinetic net adds ever (~46,000). Fiber Infrastructure bookings of ~$1.9M MRR (second-highest on record, +20% YoY). Company raised full-year 2026 revenue guidance to $3,665–$3,695M and Adjusted EBITDA to $1,460–$1,490M.

    Gap High · 43 → Very high · 50

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Forward Air CorpFWRD

    8-K · Item 2.02 — Results of operations

    Forward Air reported Q3 2026 record revenue of $674M (+6.7% YoY), operating income of $44M (nearly tripled from $15M), and consolidated EBITDA of $101M (+30.7%). All three segments performed well; liquidity improved to $446M with lowest net leverage since Q1 2024.

    Recognition: Watch 39 → Balanced 47Gap Medium · 13 → Medium · 23

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Lucid Group, Inc.LCID

    8-K · Item 2.02 — Results of operations

    Lucid reported Q3 2026 revenue of $350M (up 4% YoY despite 41% market decline), reduced cash consumption 30% sequentially to $1.04B, and secured $1.75B liquidity increase from PIF. Company advancing on four Must-Win priorities including autonomy partnerships and AMP-2 Saudi facility.

    Value: Watch 32 → Watch 27Gap Very high · 63 → Very high · 67

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Groupon, Inc.GRPN

    8-K · Item 2.02 — Results of operations

    Q3 2026: Global revenue +2%, billings +6% YoY. Loss from continuing operations $0.8M (vs. $117.8M loss prior year). Adjusted EBITDA $14.7M. Company relaunched LivingSocial as agent-first marketplace and deployed FoundryAI platform.

    Recognition: Balanced 50 → Watch 44Value: Watch 31 → Watch 27

    Market attention has faded.

    The shares became dearer on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Praxis Precision Medicines, Inc.PRAX

    8-K · Item 2.02 — Results of operations

    Praxis reported Q3 2026 results with two lead programs under FDA review (relutrigine PDUFA Dec 27, ulixacaltamide PDUFA Jan 29), $1.3B cash runway into 2028, and advancing pipeline including EMERALD topline expected Q4 2026. Commercial teams hired for both programs.

    Recognition: Watch 35 → Watch 41Gap Low · 1 → Medium · 15

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Cannae Holdings, Inc.CNNE

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show portfolio transformation progress: $793M in noncore asset sales since early 2025, $22M additional investment in Black Knight Football, Exeter Rugby acquisition, $58.8M holding company expense reduction (70%), and $111M in share repurchases year-to-date representing 16.4% of shares outstanding.

    Gap Medium · 14 → High · 25

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026All industries

    Kodiak Gas Services, Inc.KGS

    8-K · Item 2.02 — Results of operations

    Kodiak reported Q3 2026 record Compression Infrastructure revenues of $318.4M and adjusted EBITDA of $224.5M (28.5% YoY growth). Company raised full-year 2026 Adjusted EBITDA guidance to $840–860M and discretionary cash flow to $580–600M. Power Infrastructure segment showed strong 75.2% adjusted margins.

    Gap Very high · 86 → Very high · 89

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Archer Aviation Inc.ACHR

    8-K · Item 2.02 — Results of operations

    Archer achieved FAA Market Survey Special Airworthiness Certificate for Midnight, enabling LA passenger operations. Boeing acquisition (Wisk, SkyGrid, Insitu) nearing close with only one approval outstanding. Expanded partnerships with Formula 1 and ITA Airways. Q3 adjusted EBITDA in line with guidance; $1.4B liquidity.

    Gap High · 35 → High · 44

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Sable Offshore Corp.SOC

    8-K · Item 2.02 — Results of operations

    Q3 2026: $154.4M revenue (+13% QoQ), 27k net bopd (+29% QoQ). Platform Hondo nearing online (Nov 2026, ~10k bopd forecast). Perf Add operations yielding +700 bopd per well. Diversified crude sales to 3 additional LA refineries after purchaser disruption.

    Gap Medium · 20 → High · 33

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    MBX Biosciences, Inc.MBX

    8-K · Item 2.02 — Results of operations

    MBX Biosciences initiated pivotal Phase 3 oPTimize trial for canvuparatide in hypoparathyroidism; MBX 4291 obesity candidate on track for Q4 2026 data; $481.6M cash runway into 2029; expanded leadership team.

    Gap Medium · 12 → Medium · 22

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Septerna, Inc.SEPN

    8-K · Item 2.02 — Results of operations

    Septerna reported Q3 2026 results with $565.2M cash runway into mid-2029. Key pipeline progress: SEP-479 Phase 1 data expected Q1 2027; SEP-204 selected as TSHR NAM candidate with Phase 1 initiation planned Q1 2027. R&D expenses increased 51% YoY; net loss of $26.6M vs. prior year income of $8.2M.

    Recognition: Balanced 61 → Balanced 57Gap Low · 5 → Medium · 15

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Xenon Pharmaceuticals Inc.XENE

    8-K · Item 2.02 — Results of operations

    Xenon submitted NDA for azetukalner in focal seizures to FDA (September 2026); completed X-NOVA2 enrollment with December 2026 topline data expected; initiated Phase 2 studies for pain programs XEN1701 and XEN1120; cash position $1.2B with runway into 2029.

    Gap Medium · 12 → Medium · 24

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    SS&C Technologies Holdings IncSSNC

    8-K · Items 1.01, 2.03, 3.02, 8.01 — Material agreement

    SS&C completed a $1.2B convertible notes offering (upsized) due 2031 at 2.75% interest, with 25% conversion premium. Proceeds fund redemption of $2B 5.5% notes due 2027 and refinance credit facilities. Capped call hedges dilution risk.

    Value: Strong 71 → Strong 74

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    CNH Industrial N.V.CNH

    8-K · Item 1.01 — Material agreement

    CNH agreed to sell 70% of its Construction Equipment business to Kobelco for $700M cash, retaining 30% ownership. Transaction values the business at $1B enterprise value, expected to close by end of 2027. CNH transforms into pure-play agriculture company with strengthened balance sheet.

    Gap Medium · 17 → Very high · 47

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Tango Therapeutics, Inc.TNGX

    8-K · Item 2.02 — Results of operations

    Tango reported promising Phase 1/2 data for vopimetostat plus daraxonrasib combination (82% ORR, 88% 9-month PFS in pancreatic cancer), plans Phase 3 initiation in H1 2027, and maintains $977.5M cash. R&D spending increased significantly.

    Recognition: Balanced 47 → Balanced 52Gap Very high · 49 → Very high · 53

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 9 Nov 2026All industries

    Akamai Technologies IncAKAM

    8-K · Items 1.01, 2.03, 8.01 — Material agreement

    Akamai amended its credit agreement to increase leverage ratio covenants to 6.25:1.00 through Q1 2027, signaling elevated debt levels. Concurrently, it announced $2.2B convertible note offering to refinance maturing 2027 notes and fund capex, indicating near-term debt maturity pressure.

    Value: Balanced 54 → Weak 23Gap Very high · 57 → Medium · 23

    The shares became dearer on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Ionis Pharmaceuticals IncIONS

    8-K · Item 2.02 — Results of operations

    Ionis lowered 2026 TRYNGOLZA product sales guidance from $100–110M to ~$50M due to slower-than-expected launch ramp, citing gradual establishment of new treatment paradigm. DAWNZERA and total revenue guidance reaffirmed.

    Value: Watch 30 → Watch 34Gap Medium · 19 → Low · 8

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Software / SaaS

    Qualys, Inc.QLYS

    8-K · Item 2.02 — Results of operations

    Qualys reported Q3 2026 revenue of $188.0M (+11% YoY), net income of $57.2M (+14% YoY), and raised full-year 2026 revenue guidance to $736.9–$738.9M. Strong profitability metrics and product innovation drive confidence.

    Gap Low · 1 → Low · 6

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Orthofix Medical Inc.OFIX

    8-K · Item 2.02 — Results of operations

    Orthofix revised full-year 2026 guidance downward. Net sales guidance reduced from $845–855M to $825–830M; adjusted EBITDA guidance reduced from $95–100M to $86–88M. Weak U.S. Spine performance and near-term headwinds from operational restructuring cited.

    Gap Low · 5 → Low · 0

    Attention caught up with the documented progress.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Maze Therapeutics, Inc.MAZE

    8-K · Item 2.02 — Results of operations

    Maze completed enrollment in Phase 2 HORIZON trial of MZE829 exceeding targets with 50+ patients across three AMKD cohorts. Full data expected early 2027. Strong cash position of $477M supports runway into 2029. MZE782 enrollment ongoing with Phase 2 CKD trial planned for H1 2027.

    Gap Very high · 47 → Very high · 54

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 9 Nov 2026Banks

    MARA Holdings, Inc.MARA

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Balanced 50 → Balanced 47

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026All industries

    Digital Turbine, Inc.APPS

    8-K · Item 2.02 — Results of operations

    Digital Turbine reported Q2 FY2027 revenue of $178.7M (+27% YoY), GAAP net income of $10.3M vs. prior-year loss, and non-GAAP adjusted EBITDA of $39.8M (+46% YoY). Both ODS and AGP segments grew 20%+ with strong operating leverage.

    Recognition: Balanced 57 → Balanced 54Gap Low · 0 → Low · 9

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 9 Nov 2026All industries

    Uniti Group Inc.UNIT

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 43 → Very high · 50

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026All industries

    Aaon, Inc.AAON

    Quarterly report (10-Q), period ending 30 Sep 2026

    News flow: Balanced 51 → Balanced 47Gap Medium · 15 → Low · 0

    The filings read less positively.

    The gap closed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026Biotech

    Ionis Pharmaceuticals IncIONS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 30 → Watch 34Gap Medium · 19 → Low · 8

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026All industries

    GeneDx Holdings Corp.WGS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 26 → Watch 37

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Senseonics Holdings, Inc.SENS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $19.6M (+140% YoY) significantly exceeded expectations. Gross margin improved to 62%. Full-year guidance raised to $68–70M (+93–98% YoY) from $62–66M. U.S. revenue surged 160% YoY; EON Care network expanded to 100+ inserters.

    Recognition: Balanced 50 → Balanced 55Gap Low · 0 → Low · 4

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 9 Nov 2026All industries

    Virtus Investment Partners, Inc.VRTS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 42 → Watch 37Gap High · 30 → Medium · 16

    The shares became dearer on AIR's value read.

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026All industries

    Digital Turbine, Inc.APPS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 57 → Balanced 54Gap Low · 0 → Low · 9

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026All industries

    American Public Education IncAPEI

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue, net income, EPS, and adjusted EBITDA exceeded guidance. Health+ segment grew 9.0% YoY. Company raised full-year 2026 guidance across all key metrics. Institutional combination completed in August.

    Gap Medium · 15 → High · 30

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Structure Therapeutics Inc.GPCR

    8-K · Item 2.02 — Results of operations

    Structure Therapeutics reported Q3 2026 results with Phase 3 ACCOMPLISH trials for aleniglipron enrolling on schedule, positive Phase 2b extension data (16.2% weight loss), and $1.2B cash runway through 2028. R&D expenses increased significantly to support expanded clinical program.

    Gap High · 29 → High · 41

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 9 Nov 2026Biotech

    ArriVent BioPharma, Inc.AVBP

    8-K · Items 2.02, 5.02 — Results of operations

    FURVENT Phase 3 trial missed primary PFS endpoint (HR 0.75, p=0.0654). Lead R&D executive retiring. Partially offset by ADC pipeline progress and $393.2M cash runway to mid-2028.

    Gap High · 35 → Low · 2

    The gap narrowed as the filings read less positively.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026All industries

    McEwen Inc.MUX

    Quarterly report (10-Q), period ending 30 Sep 2026

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026Software / SaaS

    Qualys, Inc.QLYS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 1 → Low · 6

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Biotech

    Ocular Therapeutix, IncOCUL

    8-K · Item 2.02 — Results of operations

    Ocular Therapeutix reports Q3 2026 results with AXPAXLI NDA submission on track for 4Q 2026 following positive Pre-NDA meeting. SOL-1 post-hoc analyses show sustained durability; SOL-R designed to exclude high-risk patients. Cash position of $530.6M supports runway into 2028.

    Gap Low · 5 → Medium · 16

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026All industries

    Surgery Partners, Inc.SGRY

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Balanced 55 → Balanced 47Gap Low · 9 → Medium · 21

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 9 Nov 2026Industrials

    Sanmina CorpSANM

    8-K · Items 2.02, 8.01 — Results of operations

    Sanmina reported FY2026 revenue of $14.53B (+79% YoY), non-GAAP EPS of $13.28 (+100% YoY), and strong operating cash flow of $944M. Company raised FY2027 guidance to $17.5–$19.5B revenue (+27% midpoint) and $15.50–$17.50 non-GAAP EPS (+24% midpoint). Credit facility extended to 2031 with $70M incremental term loans.

    Value: Strong 72 → Strong 66

    The shares became dearer on AIR's value read.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 9 Nov 2026Biotech

    Tango Therapeutics, Inc.TNGX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 47 → Balanced 52Gap Very high · 49 → Very high · 53

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 9 Nov 2026Biotech

    Aura Biosciences, Inc.AURA

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 44 → Balanced 48

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 9 Nov 2026Industrials

    Orthofix Medical Inc.OFIX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 5 → Low · 0

    Attention caught up with the documented progress.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 9 Nov 2026Biotech

    Savara IncSVRA

    Quarterly report (10-Q), period ending 30 Sep 2026

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material

Routine

Friday 13 Nov76 filings read · 31 material

Thursday 12 Nov175 filings read · 119 material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.